louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00641069: Automated Chest Compression in Cardiac Arrest
Official title: Effect on Hemodynamics of Automated Band Chest Compression Device in Cardiac Arrest Resuscitation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Arrest
Keywords: Cardiac arrest
Cardiopulmonary resuscitation
Lead sponsor: Beaujon Hospital
Sponsor class: OTHER
First posted: 2008-03-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients aged \> 18 with out-of-hospital cardiac arrest

Brief summary: To evaluate the effect of use of automated chest compression device on blood pressure in patients presenting with cardiac arrest. Higher systolic, diastolic and mean blood pressures are expected.

Detailed description: The protocol compares arterial pressures produced by an automated self-adjusting load-distributing band device (AutoPulse™ 100, Zoll®) with those of manual cardiopulmonary resuscitation in refractory out-of-hospital cardiac arrest. Each patient will receive first manual compressions and then automated resuscitation.

Patients presenting with cardiac arrest are treated following standard advanced life support guidelines. They are intubated and ventilated, received epinephrine and defibrillation if appropriate. Manuel chest compressions are continued. An arterial catheter is placed to monitor hemodynamics continuously as we usually do in this case. Patients are included at this stage. Three blood pressure values (every 1 minutes) are recorded. Then, the automated band device is started up without any pause, following our procedure for refractory cardiac arrest. Three blood pressure values are recorded again, during automated cardiopulmonary resuscitation.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18
* Refractory cardiac arrest

Exclusion Criteria:

* Defective invasive arterial blood pressure monitoring

Primary outcomes:
measure: Diastolic blood pressures produced by manual and then by automated chest compressions will be recorded for each patient
timeFrame: Instantaneously
Secondary outcomes:
measure: Systolic blood pressures produced by manual and then by automated chest compressions will be recorded for each patient
timeFrame: Instantaneously
measure: Mean blood pressures produced by manual and then by automated chest compressions will be recorded for each patient
timeFrame: Instantaneously
Other outcomes:
Locations:
city: Clichy
country: France
facility: Departement of Anesthesiology, Intensive Care and EMS, Beaujon University Hospital
Study officials:
affiliation: Departement of Anesthesiology, Intensive Care and EMS, Beaujon University Hospital
name: Francois-Xavier Duchateau, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Departement of Anesthesiology, Intensive Care and EMS, Beaujon University Hospital
name: Jean Mantz, MDPhD
role: STUDY_CHAIR
References:
Clinical trial NCT01285869: Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia
Official title: Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia: a Prospective Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Community-acquired Pneumonia
Healthcare-associated Pneumonia
Keywords: Pneumonia
Intervention Studies
Aged
Aged, 80 and over
Geriatric Assessment
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
First posted: 2011-01-28
Enrollment: 314
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The hypothesis of this study is that long-term outcome in elderly patients admitted with the diagnosis of community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) would improve with a multidimensional intervention including assessment of co-morbidities, nutritional, functional and cognitive status and immunization.

Detailed description: Detailed description published in "Revista Española de Geriatría y Gerontología" (see citation and link)

Eligibility criteria: Inclusion Criteria:

* Elderly patients (aged 65 years and over), of either sex, not dependent for basic activities of daily living (Barthel index ≥60 points).
* Diagnosed with community-acquired pneumonia at the Emergency Department or Day Hospitals at "Hospital de la Santa Creu I Santa Pau"
* Admitted to hospital.

Exclusion Criteria:

* Derived from other acute care hospitals.
* Patients with HIV infection.
* Neutrophil counter\<1000/mm3
* Transplanted patients.
* Barthel index\<60 points.
* Terminal disease.
* No signed informed consent.

Primary outcomes:
measure: Healthcare resources utilization (readmissions and consultations to hospital and emergency department).
timeFrame: 1 year after hospital admission for pneumonia
Secondary outcomes:
measure: Functional status
timeFrame: 1 year after hospital admission for pneumonia
measure: Institutionalization
timeFrame: 1 year after hospital admission for pneumonia
measure: Survival
timeFrame: 1 year after hospital admission for pneumonia
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
Study officials:
affiliation: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
name: Olga H Torres, Phd
role: PRINCIPAL_INVESTIGATOR
affiliation: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
name: Domingo Ruiz, MD
role: STUDY_CHAIR
References:
citation: Torres OH, Gil E, Comas MT, Saez ME, Clotet S, Ramirez HD, Mateo M, Ruiz D. [Impact of a multidimensional intervention in elderly patients with community-acquired pneumonia: IMIEPCAP clinical trial]. Rev Esp Geriatr Gerontol. 2016 Jan-Feb;51(1):37-43. doi: 10.1016/j.regg.2015.09.004. Epub 2015 Oct 30. Spanish.
Clinical trial NCT06978569: Comparative Efficacy of ADM Hydrogel vs. Alginate Dressings in Chronic Trauma Wounds
Official title: A Randomized, Outcome Assessor-Blinded Clinical Trial Comparing the Efficacy of Acellular Dermal Matrix (ADM) Hydrogel Versus Alginate Dressings in the Treatment of Chronic Traumatic Wounds
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Trauma Wounds
Keywords: chronic wound
acellular dermal matrix
ADM
wound size
alginate
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2025-05-18
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to find out whether a wound treatment made from acellular dermal matrix (ADM) gel can help heal chronic traumatic wounds more effectively than standard alginate dressings in adults aged 18 and older with wounds that have lasted more than 3 weeks.

The main questions it aims to answer are:

Does ADM gel reduce the size of chronic wounds more than alginate dressings after 12 weeks?

Does ADM gel help wounds heal faster and improve quality of life for patients?

Researchers will compare ADM gel to alginate dressings to see if the ADM gel leads to better healing results and fewer complications.

Participants will:

Be randomly assigned to receive either ADM gel or alginate dressing.

Have the treatment applied directly to their cleaned wound.

Attend weekly visits for up to 12 weeks for wound checks, measurements, and dressing changes.


Eligibility criteria: Inclusion Criteria:

* Chronic trauma wounds persisting ≥3 weeks.
* Wound size between 4 and 20 cm² and depth ≤9 mm on the lower limbs.
* Willingness and ability to provide informed consent.
* Wounds without uncontrolled infection

Exclusion Criteria:

* Wounds with exposed bone.
* Current use of immunomodulators, corticosteroids, immunosuppressive or cytotoxic drugs.
* Pregnant individuals.
* Significant reduction (≥30%) of wound size during a 2-week run-in phase.
* Concurrent participation in another clinical trial involving drugs.
* Wounds with uncontrolled infection
* Allergy or hypersensitivity to components of ADM gel or alginate

Primary outcomes:
measure: Wound surface area (cm²) at Week 12, adjusted for baseline wound size
timeFrame: Week 1 and 12
Secondary outcomes:
measure: Time to complete wound healing (100% epithelialization)
timeFrame: Weekly up to 12 weeks
measure: Rate of granulation tissue formation
timeFrame: Weekly up to 12 weeks
measure: Rate of wound epithelialization
timeFrame: Weekly up to 12 weeks
measure: Incidence of complications (infection, necrosis, bleeding)
timeFrame: Up to 12 weeks
measure: Quality of life score at Week 12
timeFrame: Weeks 1 and 12
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Alzahra hospital
Study officials:
References:
Clinical trial NCT01029769: Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
Official title: The Switch Study - Efficacy of Early Antipsychotic Switch Versus Maintenance in Patients With Schizophrenia Poorly Responding to Two Weeks of Antipsychotic Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2009-12-10
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The main aim of the trial is to study whether a change of medication in non-responders to a two-weeks antipsychotic drug trial is more effective than continued treatment with the same antipsychotic. Hypothesis: Non-responders who are switched at 2 weeks to another antipsychotic are more frequently in symptomatic remission at week 8 than non-responders who stay on the same antipsychotic

Detailed description: The patients will be randomised to a double-blind 2 week run in phase with fixed doses of either oral amisulpride 800 mg/day or olanzapine 20mg/day.

Those participants who have not responded to treatment at two weeks (PANSS improvement \<25%) will be randomised to a 6 week double blind flexible dose phase:

1. Experimental intervention: switch to the other antipsychotic (oral olanzapine 5-20mg/d or oral amisulpride 200-800 mg/d)
2. Control intervention: continuation with the same drug as in the first 2 weeks in flexible dose ranges as above for another six weeks Those participants who have responded at week 2 (≥25% PANSS reduction) will continue on the same drug in flexible dose ranges as above Total duration of intervention per patient: 8 weeks

Eligibility criteria: Inclusion Criteria:

* Inpatients with Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Revision (DSM-IV TR) diagnosis of schizophrenia, schizophreniform or schizoaffective disorder
* PANSS total score at baseline \> 75, at least two PANSS psychosis items ≥ 4, Clinical Global Impression of severity score moderately ill or more (≥4)
* Increase in the level of care (outpatient care to day clinic or inpatient care)

Exclusion Criteria:

* contraindication to study drugs

Primary outcomes:
measure: Number of Patients in Symptomatic Remission at Week 8 Comparing the "Switched" With the "Non Switched" Early Non-responders
timeFrame: 8 weeks
Secondary outcomes:
measure: PANSS Total Score Change
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Munic
country: Germany
facility: Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar
state: Bavaria
Study officials:
affiliation: Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universität München am Klinikum rechts der Isar
name: Stefan Leucht, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06441669: Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
Official title: Effect of Letermovir Prophylaxis on Cytomegalovirus-specific Immune Reconstitution Post Unrelated Cord Blood Transplantation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cytomegalovirus Infection Reactivation
Keywords: Cytomegalovirus Infection
Umbilical Cord Blood Transplantation
CMV-Specific Immune Reconstitution
Letermovir
Lead sponsor: Anhui Provincial Hospital
Sponsor class: OTHER_GOV
First posted: 2024-06-04
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study consists 60 cases recipients of UCBT. All patients will receive letermovir prophylaxis within 0-28 days post UCBT.

Brief summary: To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

Detailed description: To explore the effect of letermovir prophylaxis on cytomegalovirus-specific and other lymphocyte subsets immune reconstitution post unrelated cord blood transplantation, and to analyze the potential mechanism and risk factors of late CMV reactivation after letermovir discontinuation.

Eligibility criteria: Inclusion Criteria:

* Patients are receiving a first unrelated cord blood transplantation (UCBT).
* Patients start letemovir prophylaxis within 0-28 days post UCBT.

Exclusion Criteria:

* Patients having active CMV DNAemia at the time of letermovir initiation.
* Patients recruited in a clinical study on an anti-CMV trial.

Primary outcomes:
measure: Numbers of immune cells in peripheral blood
timeFrame: one year
measure: CMV DNAemia
timeFrame: one year
measure: Incidence of refractory CMV infection
timeFrame: one year
measure: late CMV reactivation
timeFrame: one year
Secondary outcomes:
measure: Treatment-ralated mortality
timeFrame: one year
measure: Incidence of other viral infection and viral-associated disease
timeFrame: one year
measure: Overall survival
timeFrame: one year
measure: serum immunoglobulin assay
timeFrame: 1,3,6,9 month post UCBT
Other outcomes:
Locations:
city: Hefei
country: China
facility: Anhui Provincial Hospital
state: Anhui
Study officials:
affiliation: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)
name: Xiaoyu Zhu, ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02782169: Prophylactic Pregabalin to Decrease Pain During Medical Abortion
Official title: Prophylactic Pregabalin to Decrease Pain During Medical Abortion: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Pain
Lead sponsor: University of Hawaii
Sponsor class: OTHER
Collaborators: name: Society of Family Planning
First posted: 2016-05-25
Enrollment: 110
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Medical abortion has been associated with significant pain. The objective of this trial is to determine whether one dose of pregabalin 300 mg, given during medical abortion in addition to the standard of care analgesics, will decrease experienced pain. Investigators will perform a randomized, double-blinded, placebo-controlled trial. Participant pain levels and side effects will be assessed at multiple time points, along with a measure of satisfaction.


Eligibility criteria: Inclusion Criteria:

* Requested and consented for pregnancy termination by medical abortion
* Willing and able to complete multiple electronic surveys

Exclusion Criteria:

* Previous participation in this trial
* Current use of pregabalin or gabapentin
* Contraindication to medical abortion with mifepristone and misoprostol
* Contraindication or allergy to ibuprofen, oxycodone, acetaminophen, or pregabalin
* Unable to understand and sign written informed consents in English

Primary outcomes:
measure: Maximum Pain Score Over Study Period
timeFrame: Over 72 hours (measured at 0, 2, 6, 12, 24, and 72 hours)
Secondary outcomes:
measure: Number of Ibuprofen 800mg Tablets Used
timeFrame: Over 72 hours (measured at 0, 2, 6, 12, 24, and 72 hours)
measure: Number of Oxycodone/Acetominophen Tablets (5/325mg) Used
timeFrame: Over 72 hours (measured at 0, 2, 6, 12, 24, and 72 hours)
measure: Number of Participants Ever Experiencing Different Symptoms During Abortion
timeFrame: Over 72 hours (measured at 0, 2, 6, 12, 24, and 72 hours)
measure: Satisfaction With Analgesia
timeFrame: Asked at time point of 24 hours
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Women's Options Center
state: Hawaii
Study officials:
References:
citation: Reynolds-Wright JJ, Woldetsadik MA, Morroni C, Cameron S. Pain management for medical abortion before 14 weeks' gestation. Cochrane Database Syst Rev. 2022 May 13;5(5):CD013525. doi: 10.1002/14651858.CD013525.pub2.
citation: Friedlander EB, Soon R, Salcedo J, Davis J, Tschann M, Kaneshiro B. Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018 Sep;132(3):612-618. doi: 10.1097/AOG.0000000000002787.
Clinical trial NCT05753969: The Efficacy of "Mindtesion"is Measuring Attentional and the Startle Response Dysregulation in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.
Official title: The Efficacy of "Mindtesion"is Measuring Attentional and the Startle Response Dysregulation in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Attention Deficit Disorder With Hyperactivity
Keywords: ADHD
Attention
Lead sponsor: Geha Mental Health Center
Sponsor class: OTHER
First posted: 2023-03-03
Enrollment: 200
Sex: ALL
Minimum age (years): 7
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Double blind, placebo-controlled clinical study designed to evaluate Mindtension device and Protocol as a diagnostic tool in children diagnosed with ADHD

Detailed description: Mindtension device measures the orbicularis muscle response to auditory stimuli, the device is backed up by an algorithm that calculate the several parameters of startle reflex such as the Paired-pulse inhibition (PPI), Habituation, and startle related indices.

Data collected by the device is used to evaluate the subject levels of attention, Hyperarousal and Impulsivity, by means of physiological EMG signals of the startle response.

Evaluating baseline differences in these parameters between ADHD and age matched healthy controls, and the possible improvement after psychostimulant medications.

Eligibility criteria: Inclusion Criteria:

(i) Children with ADHD according to DSM-5 criteria in a semi-structured interview by a senior psychiatrist.

(ii) Reaching 85 percent score on the ADHD-RS scale. (iii) Treated with a stimulant in the perceived optimal dosage.

Exclusion Criteria:

(i) autism spectrum disorder. (ii) chronic neurological disorders and chronic medical conditions (e.g., diabetes).

(iii) schizophrenia spectrum and other psychotic disorders. (iv) substance abuse (drugs or alcohol). (v) depression. (vi) hearing loss. (vii) lack of cooperation.

Primary outcomes:
measure: Mindtension EMG values
timeFrame: baseline and 1 hour post treatment
measure: ADHD severity
timeFrame: Baseline
measure: Impulsive dysregulation
timeFrame: Baseline
Secondary outcomes:
measure: CBCL
timeFrame: Baseline
measure: Changes in treatment
timeFrame: Baseline
Other outcomes:
Locations:
city: Petah Tikwah
country: Israel
facility: ADHD clinic, Dan Petach-Tiqva, Geha MHC, Clalit
Study officials:
References:
Clinical trial NCT00800969: Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Adenocarcinoma
Stomach Cancer
Cancer of Esophagogastric Junction
Keywords: Adenocarcinoma of the stomach and esophagogastric junction
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2008-12-03
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This prospective study includes patients with histologically proven cancer of the esophagogastric junction (Siewert Type II and III) and the stomach. Aim of the study is to evaluate the accuracy of PET-CT for the preoperative assessment of lymph node metastasis. The evaluation includes a combination with standard diagnostic tools (endoluminal ultrasound, CT and diagnostic laparoscopy prior to neoadjuvant therapy). Standardized D2-lymphadenectomy is performed and individual lymph node stations (Nr 1-12 according to the Japanese classification) are histopathologically examined. Furthermore we evaluate the role of the PET-CT for early metabolic response evaluation in patients receiving neoadjuvant chemotherapy.

* Trial with surgical intervention


Eligibility criteria: Inclusion criteria:

* Histological prove of adenocarcinoma of the stomach.

Exclusion criteria:

* Recurrent gastric carcinoma
* No informed consent
* Previous malignancy (exception: thyroid, bladder in situ, Cervix in situ)

Primary outcomes:
measure: Diagnostic Accuracy of PET-CT
timeFrame: preoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
Study officials:
affiliation: University Hospital Zurich, Visceral surgery
name: Kuno Lehmann, MD
role: PRINCIPAL_INVESTIGATOR
References: